

Miptenalimab Biosimilar - Research Grade

Product Code: ICH5259

More Information

Species Reactivity: Human

Target: LAG3

Concentration: >1mg/ml

Isotype: Human IgG4 - kappa

Host: CHO Cells

product name H2: Miptenalimab Biosimilar - Research Grade

Antibodies against the same target: [Anti-Mouse LAG-3 \(C9B7W\) In Vivo Antibody - Low Endotoxin \(ICH1078\)](#), [TSR-033 Biosimilar - Research Grade \(ICH5067\)](#), [Ieramilimab Biosimilar - Research Grade \(ICH5098\)](#), [Relatlimab Biosimilar - Research Grade \(ICH5117\)](#), [Encelimab Biosimilar - Research Grade \(ICH5524\)](#), [Favezelimab Biosimilar - Research Grade \(ICH5545\)](#), [Fianlimab Biosimilar - Research Grade \(ICH5548\)](#), [Negalstobart Biosimilar - Research Grade \(ICH5704\)](#), [Tuparstobart Biosimilar - Research Grade \(ICH5948\)](#)

Sequence: <https://www.imgt.org/mAb-DB/>

Buffer: ICH3002

UniProt: P18627

Shipping Conditions: Blue ice

background: This product is an unconjugated, non-therapeutic recombinant analog of miptenalimab, an anti-LAG-3 (CD223) antibody, supplied on a human IgG4 kappa framework and built around the human LAG-3 target (UniProt P18627). It is manufactured for research use only and is not the clinical drug; it is not intended for human or veterinary

use. The preparation is provided unconjugated and functions as a research-grade tool for interrogating the LAG-3 immune-checkpoint axis in vitro and in preclinical settings. Typical applications include use as a positive binding or blocking control, a reference reagent in checkpoint-blockade assays, a capture or detection component in immunoassays, and a scaffold for antibody-engineering or ADC/bispecific development workflows. It is available at low endotoxin (research grade 1 EU/mg; ultra-low 0.5 EU/mg options), which suits sensitive cell-based and functional work, and can be produced in bulk milligram-to-gram quantities for screening campaigns and assay standardisation. As an analog rather than the originator product, it is intended to support comparability, method development, and mechanistic research programs. LAG-3 (lymphocyte activation gene 3; CD223) is a type I transmembrane immune-checkpoint receptor structurally related to CD4, expressed on activated T cells, regulatory T cells, natural killer cells, B cells, and plasmacytoid dendritic cells. Its principal ligand is MHC class II, to which it binds with higher affinity than CD4; additional reported ligands include fibrinogen-like protein 1 (FGL1), galectin-3, and LSECtin. Engagement transmits an inhibitory signal that dampens T-cell proliferation, cytokine production, and effector function, and it contributes to the exhausted phenotype of tumour- and chronically-infected-tissue-infiltrating lymphocytes. LAG-3 frequently co-expresses with PD-1, and co-blockade produces additive restoration of T-cell activity, making LAG-3 a validated checkpoint target for cancer immunotherapy research and combination-blockade studies.

Other names: Lymphocyte activation gene 3 protein, FDC

Specificity: Detects human LAG3

Purification Method: This monoclonal antibody was purified using Protein A

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >95% by SDS-PAGE

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.



Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.